PhD in Next-generation CAR T-cell Therapy for Solid Tumours and Prostate Cancer
PhD opportunity in
next-generation CAR T-cell therapy
for
solid tumours
, with a focus on
prostate cancer
, at
Aarhus University
(Department of Biomedicine, Faculty of Health, Aarhus, Denmark).
The project is part of a larger effort to improve solid tumour therapy using engineered immune cells that can seek and kill cancer cells while also delivering a drug to improve tumour penetration and therapeutic potency. The work sits at the intersection of
immune cell engineering
,
drug delivery
,
cancer therapy
, and translational biomedical research. The project is described as fully funded and will involve a highly interdisciplinary research environment with state-of-the-art facilities and international collaborators.
Research activities may include wet-lab molecular biology, mammalian cell culture, drug evaluation, flow cytometry, imaging, and related experimental work. The call notes that collaboration with
Karolinska Institutet
in Stockholm is important, and a mandatory stay abroad there at the beginning of the project would be advantageous.
Eligibility highlights include a Master’s degree in
molecular medicine
,
molecular biology
,
biomedical engineering
, or a related field; experience with cloning, PCR/qPCR, western blotting, gel electrophoresis, cell culture, and drug/viability assays is preferred. Experience with RNA or peptide therapeutics, in vivo cancer models, and pharmacokinetic/pharmacodynamic evaluations is a plus. Applicants should have strong English skills, analytical ability, independence, attention to detail, and good communication skills for an international team.
Deadline:
3 May 2026, 23:59 CET.
Preferred start date:
1 August 2026.
To apply, use the application link and consult Aarhus University’s application guide for predefined PhD projects and mandatory attachments.
